Oragenics
OGEN
24 hedge funds and large institutions have $3.61M invested in Oragenics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
8% less funds holding
Funds holding: 26 → 24 (-2)
27% less capital invested
Capital invested by funds: $4.96M → $3.61M (-$1.35M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$31.5K |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.7K |
| 3 |
Jane Street
New York
|
+$6.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.13K |
| 5 |
Millennium Management
New York
|
+$2.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$183K |
| 2 |
VF
Virtu Financial
New York
|
-$60.9K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$24K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$15.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| – | +$733 | +1 | New |
|
OGEN Hedge Fund Activity: Q1 2022 in Review
24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q1 2022, worth a combined $3.61M — down 27% from $4.96M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of OGEN and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $31.5K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $183K sold.
- 24 institutional investors held Oragenics (OGEN) as of Q1 2022, down from 26 in Q4 2021.
- Funds reported $3.61M of Oragenics stock for Q1 2022, down 27% quarter-over-quarter.
- 1 fund opened new Oragenics positions in Q1 2022 and 3 closed out, a net change of -2 holders.
- The largest Oragenics buyer in Q1 2022 was Renaissance Technologies, an estimated $31.5K added.
- The largest Oragenics seller in Q1 2022 was GSA Capital Partners, an estimated $183K sold.
Based on aggregated 13F filings for Q1 2022.